The biopharmaceutical industry is undergoing a significant transformation as it increasingly embraces precision medicines, a trend propelled by the necessity for enhanced potency and innovative mechanisms of action. Atul Mohindra, Head of Biologics R&D at Lonza, disclosed in an interview with BioPharmInternational.com that this shift involves a notable movement towards the development of more complex formulations of monoclonal antibodies.
"The need for increasing precision medicine [and] reducing off target events is always going to be there, and I think that's exactly where the industry needs to head," Mohindra explained. He emphasised that the industry's focus on precision medicine corresponds with the rising incorporation of artificial intelligence (AI) technologies and improvements in analytical testing methodologies. Furthermore, he pointed out that these advancements could be coupled with more efficient bioprocessing techniques, such as continuous bio processing, indicating a forward momentum in the industry's approach.
As the industry witnesses a burgeoning wave of complex proteins in the pipeline, particularly in the Phase I and II stages of development, the growth of bispecific molecules is becoming increasingly apparent. Currently, FDA-approved products encompass only a limited number of these complex entities. However, Mohindra anticipates a more substantial influx of such innovations, widening their applications to treat a variety of conditions, including autoimmune diseases, neurological disorders, and infectious diseases.
Despite these advancements, Mohindra noted that the industry must enhance its analytical technologies and strive towards more cost-effective bioprocess solutions. He commented on the industry's trajectory, stating that "advancement in the use of more complex proteins with more wider applications" will necessitate a push in both analytical and operational dimensions.
Atul Mohindra is a seasoned professional within the biopharmaceutical landscape, having dedicated nearly two decades to Lonza. He oversees a global team of over 200 scientists, all engaged in the development and implementation of pioneering technologies at the company's Biologics division. His expertise encompasses the successful development and application of multiple novel processes for cell culture, purification, and analytical platforms related to a range of innovator and biosimilar programmes. In addition to his responsibilities at Lonza, Mohindra also contributes as a board observer for Affinia Therapeutics, a biotech entity focused on gene therapies.
This evolving landscape of AI automation and enhanced bioprocessing within the biopharmaceutical industry illustrates a future that could bring revolutionary advancements in treatment methods and patient care, mirroring the industry's commitment to scientific innovation.
Source: Noah Wire Services